Page last updated: 2024-11-07

morpholinoanthracycline mx2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

morpholinoanthracycline MX2: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6917994
MeSH IDM0151641

Synonyms (19)

Synonym
krn-8602
mx2
5,12-naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-((2,3,6-trideoxy-3-(4-morpholinyl)-alpha-l-lyxo-hexopyranosyl)oxy)-
5,12-naphthacenedione, 7,8,9,10-tetrahydro-8-ethyl-10-((3-(4-morpholinyl)-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-1,6,7,8,11-pentahydroxy-
morpholinoanthracycline mx2
morpholinyl oxaunomycin
nsc-619003
(7s,9r,10r)-9-ethyl-4,6,9,10,11-pentahydroxy-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-8,10-dihydro-7h-tetracene-5,12-dione
morpholinoanthracycline mx-2
105026-50-4
3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin
g0j883cj9m ,
unii-g0j883cj9m
mx-2
3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin
(7s,9r,10r)-3'-deamino-3'-(4-morpholinyl)-13-deoxo-10-hydroxycarminomycin
5,12-naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-((2,3,6-trideoxy-3-(4-morpholinyl)-.alpha.-l-lyxo-hexopyranosyl)oxy)-, (7r,8r,10s)
krn 8602 free base
krn-8602 free base

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The LD50 values for MX2, M2 and BCNU were 10."( An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
Hill, JS; Kaye, AH; Park, SJ, 2000
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic properties of KRN 8602, an anthracycline compound, was studied by HPLC following intravenous administration of KRN 8602 to cancer patients."( [Pharmacokinetics of KRN 8602 in cancer patients].
Majima, H; Shinkai, H, 1991
)
0.28
" To elucidate this discrepancy, pharmacokinetic analysis and MTT assay were conducted using the KRN8602-sensitive MX-1 and KRN8602-insensitive R-27."( Antitumor activity and pharmacokinetics of a morpholino-anthracycline derivative (KRN8602) against human breast carcinoma xenografts serially transplanted into nude mice.
Abe, O; Asanuma, F; Ishibiki, K; Josui, K; Kawamura, E; Koh, J; Kubota, T; Shiina, E; Suto, A; Yamada, Y, 1990
)
0.28
"68 l/min, the mean volume of distribution at steady state was 1460 +/- 749 l and mean elimination half-life was 10."( Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
Basser, RL; Cebon, J; Clarke, K; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, DW; Morgan, DJ; Park, SJ; Stylli, SS, 1997
)
0.3
"The mean fast distribution half-life (1."( Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease.
Basser, RL; Cebon, J; Clarke, K; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, DW; Morgan, DJ; Park, SJ; Stylli, SS, 1998
)
0.3
" Pharmacokinetic parameters showed substantial variation, although the area under the plasma concentration-time curve (AUC) and maximum concentration both increased with dose."( Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.
Alt, C; Bartlett, J; Basser, RL; Cebon, J; Clarke, K; Fox, RM; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, D; Morgan, DJ, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" KRN8601 was infused intravenously at a dosage of 200 micrograms/m2 for 14 consecutive days."( [Phase III clinical trial of KRN8601 (rhG-CSF) for neutropenia in patients with human immunodeficiency virus infection].
Fukue, H; Fukutake, K; Gohchi, K; Ishigatsubo, Y; Kimura, S; Koitabashi, Y; Matsuda, J; Okubo, T; Shimada, K; Yamada, K, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (13.73)18.7374
1990's39 (76.47)18.2507
2000's5 (9.80)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (28.30%)5.53%
Reviews3 (5.66%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (66.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]